Skip to main content

GNOM

ETF
—
—

Performance overview

GNOM Price
Price Chart

Forward-looking statistics

Beta
1.06
Risk
28.64%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Fund info

The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Investing methodPassively Managed
DiversifiedNo
Expense ratio0.50%
Asset classUnknown

Company info

Sector—
Industry—
Website—
AUM—

Security info

ExchangeNASDAQ
Type of shareN/A
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$351K
Avg trading volume (10 day)$395K
Put-call ratioN/A

Macro factor sensitivity

Growth-0.8
Credit+5.3
Liquidity-0.3
Inflation-3.1
Commodities-0.0
Interest Rates-2.1

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend dayJune 27, 2025

News

Will 2023 be the Year of Cathie Wood ETFs?

Cathie Wood, famous for the success of Ark Investment???s winning products, had faced a miserable fate in 2022.

Zacks Investment Research (January 24, 2023)
Three tech subgroups can keep climbing despite the sector's record run, ETF analyst says

Investors should consider buying into genomics, cloud computing and video gaming ETFs as tech trades near records, Global X's Jay Jacobs says.

CNBC (August 5, 2020)
3 Genomics ETFs Worth Jumping For

The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are delivering impressive returns.

Benzinga (May 26, 2020)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free